HIV Infections Clinical Trial
Official title:
Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trials on the Effect of Combination of TCM and HAART on Immune Reconstitution of HIV/AIDS Patients
Immunity 1 (Fuzheng 1) is composed of herbs which have tonic and detoxific function. The long-term clinical application has proved the safety and effect. It can improve the symptoms and signs in AIDS patients with the effective rate of 70% and can significantly improve the quality of life. It can also improve and stabilize immune function and inhibit viral replication. The basis study have shown that Immunity 1 (Fuzheng 1) can inhibit viral replication from multi-target, multi-link, enhance immune function, increase the secretion of IL-2, IFN-γ, participate in immune regulation effect, enhance NK cell activity, promote CD3+CD4+T cell proliferation and increase macrophage phagocytes capacity.
- Meng Kun found that Joint application of Chuankezhi can enhance the number of CD4 cells
and reduce side-effects of HAART compared with HAART alone. in order to verify the
long-term efficacy of combination therapy, they carried out an clinical observations of
three cases of patients who received combination therapy for over a period of 3 years,
through the observation of three cases of patients, they found that CD3+CD4+T
lymphocyte count were significantly increased and HIV-RNA viral load were below
50copies for long-term, and without the occurrence of drug resistance. And the
patient's symptoms and signs have also been significantly improved.
- Duan Cheng Yu analyses 334 cases of AIDS patients' clinical symptoms, signs and
Karnofsky score, and CD3+CD4+ T lymphocyte count before and after treatment. The
patients all take "kang ai bao sheng" capsules for 3 months. The results showed that
334 cases of patients receiving traditional Chinese and western medicine treatment
shows improvement in symptoms and signs, increase in CD3+CD4+ T lymphocyte count. They
proposed that combination of traditional Chinese and western medicine can improve
symptoms, enhance immunity function and improve the quality of life of AIDS patients.
- In order to observe the effect of combination of TCM and HAART on HIV/AIDS patients,
ZHANG Ai-min divided 63 cases of AIDS into 3 groups. 20 cases received TCM treatment
and 22 cases received combination of TCM and HAART, 21 cases received western medicine.
The patients' symptoms, signs, Karnofsky score points, CD3+CD4+T lymphocyte counts and
HIV-RNA viral load were recorded and compare the difference between the 3 groups. The
results showed that combination treatment can more effectively improve the immune
function of HIV/AIDS patients, reduce HIV-RNA viral load, and improve the patients'
symptoms, signs and the quality of life.
- Immunity 1 (Fuzheng 1) is composed of herbs which have tonic and detoxific function.
The long-term clinical application has proved the safety and effect. It can improve the
symptoms and signs in AIDS patients with the effective rate of 70% and can
significantly improve the quality of life. It can also improve and stabilize immune
function and inhibit viral replication. The basis study have shown that Immunity 1
(Fuzheng 1) can inhibit viral replication from multi-target, multi-link, enhance immune
function, increase the secretion of IL-2, IFN-γ, participate in immune regulation
effect, enhance NK cell activity, promote CD3+CD4+T cell proliferation and increase
macrophage phagocytes capacity.
- Through the clinical trials, we are going to evaluate the efficacy and safety of
combination of TCM and HAART on immune reconstitution of HIV/AIDS patients.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |